Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Skincerity + sirolimus
- Development stage
- Unknown
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Skincerity + sirolimus is an investigational topical formulation developed by the University of Texas Health Science Center at Houston in collaboration with Biomedical Development Corporation. It consists of the mTOR inhibitor sirolimus (also known as rapamycin) compounded into Skincerity®, a proprietary film-forming technology composed of a breathable Polyvinylidene fluoride (PVDF) coating. This "liquid bandage" delivery system is designed to provide localized delivery of sirolimus to cutaneous lesions, specifically facial angiofibromas in patients with Tuberous Sclerosis Complex (TSC) and cutaneous neurofibromas in patients with Neurofibromatosis Type 1 (NF1). By inhibiting the mTOR pathway, which is constitutively active in these genetic disorders, the treatment aims to reduce the size and appearance of fibromatous skin lesions while minimizing systemic absorption and associated side effects.
- Other names
- Skincerity plus sirolimusSkincerity plus rapamycinTopical rapamycinTopical sirolimusPVDF coating containing rapamycin
02
Targets
mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on Skincerity + sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skincerity + sirolimus.